Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management
Bo Xu, Shaoqian Li, Bo-Kyeong Kang, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 116

Showing 1-25 of 116 citing articles:

Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies
Idoia Genua, Kenneth Cusi
Diabetes Spectrum (2024) Vol. 37, Iss. 1, pp. 48-58
Open Access | Times Cited: 29
Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress
Clara Luna-Marco, Francesca Iannantuoni, Alberto Hermo-Argibay, et al.
Free Radical Biology and Medicine (2024) Vol. 213, pp. 19-35
Open Access | Times Cited: 28
Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis
Muhammad Usman, Deepak L. Bhatt, Ishaque Hameed, et al.
The Lancet Diabetes & Endocrinology (2024) Vol. 12, Iss. 7, pp. 447-461
Closed Access | Times Cited: 27
Impaired skeletal muscle regeneration in diabetes: From cellular and molecular mechanisms to novel treatments
Ever Espino‐Gonzalez, Emilie Dalbram, Rémi Mounier, et al.
Cell Metabolism (2024) Vol. 36, Iss. 6, pp. 1204-1236
Open Access | Times Cited: 24
Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies
Keong Chong, Jack. Keng-Jui Chang, Lee‐Ming Chuang
The Kaohsiung Journal of Medical Sciences (2024) Vol. 40, Iss. 3, pp. 212-220
Open Access | Times Cited: 18
Fibrosis in Chronic Kidney Disease: Pathophysiology and Therapeutic Targets
Allison B. Reiss, Berlin Jacob, Aarij Zubair, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 7, pp. 1881-1881
Open Access | Times Cited: 17
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Nervous System Disorders: A Systematic Review and Meta-Analysis
Bo Xu, Mingxia Yang, Shaoqian Li, et al.
Annals of Pharmacotherapy (2025)
Closed Access | Times Cited: 3
Adipocyte Regulation of Insulin Sensitivity and the Risk of Type 2 Diabetes
Anna Santoro, Barbara B. Kahn
New England Journal of Medicine (2023) Vol. 388, Iss. 22, pp. 2071-2085
Closed Access | Times Cited: 40
Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction
Arjun Pandey, Deepak L. Bhatt, Avinash Pandey, et al.
European Heart Journal (2023) Vol. 44, Iss. 37, pp. 3640-3651
Closed Access | Times Cited: 37
Signaling pathways and intervention for therapy of type 2 diabetes mellitus
Rong Cao, Huimin Tian, Yu Zhang, et al.
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 27
Sex differences in cardiovascular outcomes of SGLT-2 inhibitors in heart failure randomized controlled trials: A systematic review and meta-analysis
Frederick Berro Rivera, Vincent Anthony S. Tang, Deogracias Villa De Luna, et al.
American Heart Journal Plus Cardiology Research and Practice (2023) Vol. 26, pp. 100261-100261
Open Access | Times Cited: 26
SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system
Jiaqi Mei, Yi Li, Liyan Niu, et al.
Translational Neurodegeneration (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 15
Clinical features, treatment, and prognosis of SGLT2 inhibitors induced acute pancreatitis
Ronghui Li, Panpan Luo, Yuge Guo, et al.
Expert Opinion on Drug Safety (2024), pp. 1-5
Closed Access | Times Cited: 13
Targeting inflammatory signaling pathways with SGLT2 inhibitors: Insights into cardiovascular health and cardiac cell improvement
Fatmah R. Alsereidi, Zenith Khashim, Hezlin Marzook, et al.
Current Problems in Cardiology (2024) Vol. 49, Iss. 5, pp. 102524-102524
Closed Access | Times Cited: 12
The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment
Eleni Michalopoulou, J Thymis, Stamatios Lampsas, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 2, pp. 428-428
Open Access | Times Cited: 1
Unlocking the power of empagliflozin: Rescuing inflammation in hyperglycaemia‐ exposed human cardiomyocytes through comprehensive multi‐level analysis
Rosaria Benedetti, Ugo Chianese, Chiara Papulino, et al.
European Journal of Heart Failure (2025)
Open Access | Times Cited: 1
The efficacy of sodium-glucose transporter 2 inhibitors in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis
Hongsheng Li, Yanli Hou, Xin Wang, et al.
Pharmacological Research (2025) Vol. 213, pp. 107647-107647
Open Access | Times Cited: 1
Canagliflozin reduces chemoresistance in hepatocellular carcinoma through PKM2-c-Myc complex-mediated glutamine starvation
Yuan Zeng, Haoran Jiang, Xiangting Zhang, et al.
Free Radical Biology and Medicine (2023) Vol. 208, pp. 571-586
Closed Access | Times Cited: 19
Effects of Liraglutide, Empagliflozin and Their Combination on Left Atrial Strain and Arterial Function
Κ Katogiannis, J Thymis, Foteini Kousathana, et al.
Medicina (2024) Vol. 60, Iss. 3, pp. 395-395
Open Access | Times Cited: 7
The gut-liver axis: emerging mechanisms and therapeutic approaches for nonalcoholic fatty liver disease and type 2 diabetes mellitus
Monika Bhardwaj, Papiya Mitra Mazumder
Naunyn-Schmiedeberg s Archives of Pharmacology (2024)
Closed Access | Times Cited: 7
Metabolic reprogramming in septic acute kidney injury: pathogenesis and therapeutic implications
Caihong Liu, Wei Wei, Yongxiu Huang, et al.
Metabolism (2024) Vol. 158, pp. 155974-155974
Closed Access | Times Cited: 7
Vitamin D Alleviates Type 2 Diabetes Mellitus by Mitigating Oxidative Stress-Induced Pancreatic β-Cell Impairment
Jia Liu, Yuanjun Zhang, Derong Shi, et al.
Experimental and Clinical Endocrinology & Diabetes (2023) Vol. 131, Iss. 12, pp. 656-666
Open Access | Times Cited: 14
Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis
Shunichiro Tsukamoto, Ryutaro Morita, Takayuki Yamada, et al.
Diabetes Research and Clinical Practice (2022) Vol. 194, pp. 110161-110161
Closed Access | Times Cited: 21
The Effects of Cardioprotective Antidiabetic Therapy on Microbiota in Patients with Type 2 Diabetes Mellitus—A Systematic Review
Cristina Bică, Valeria-Anca Pietroșel, Teodor Salmen, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 8, pp. 7184-7184
Open Access | Times Cited: 11
Natural exosomes-like nanoparticles in mung bean sprouts possesses anti-diabetic effects via activation of PI3K/Akt/GLUT4/GSK-3β signaling pathway
Cheng-Xun He, Ke Wang, Jun Xia, et al.
Journal of Nanobiotechnology (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top